Therefore, an advantage of this study is that it confirms that NRI and SIRI are the optimal combination model for predicting prognosis for NSCLC patients treated with EGFR-TKI, especially NSCLC patients with TNM stage IV. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.